All In Biotech

Drug Trial Radar · NCT01138007

A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)

Study AK1113351, a Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD) - a Multi-center, Placebo-controlled, Randomized, Double-blind, Parallel-comparison Study

Last checked: Nov 20, 2026Latest source record: Aug 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 572 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

572

Actual

Start

Jun 17, 2010

Primary completion

Aug 1, 2012

Study completion Aug 7, 2012

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 7, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study to confirm the efficacy of 323U66 Sustained Release (SR) orally administered to patients with MDD (Major Depressive Disorder) at doses level of 150 mg/day and 300 mg/day for 8 weeks based on the decrease in MADRS (Montgomery-Asberg Depression Rating Scale) total score, and to evaluate the safety based on adverse events, clinical laboratory tests and vital signs.

Conditions

  • Depressive Disorder, Major

Interventions

  • 323U66 SR 150 mg tabletDrug

    323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.

  • 323U66 SR 150 mg placebo tabletDrug

    323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/WithdrawalTime frame: Baseline and Week 8/Withdrawal

Locations

59 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukushima, Japan

  • GSK Investigational Site

    Fukushima, Japan

  • GSK Investigational Site

    Fukushima, Japan

  • GSK Investigational Site

    Hiroshima, Japan

  • GSK Investigational Site

    Hyōgo, Japan

  • GSK Investigational Site

    Ibaraki, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kumamoto, Japan

  • GSK Investigational Site

    Kyoto, Japan

  • GSK Investigational Site

    Nara, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Saga, Japan

  • GSK Investigational Site

    Saga, Japan

  • GSK Investigational Site

    Saga, Japan

  • GSK Investigational Site

    Saitama, Japan

  • GSK Investigational Site

    Shizuoka, Japan

  • GSK Investigational Site

    Tochigi, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.